Compare AstraZeneca plc (AZN) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Boston Scientific Corporation — how do they compare? AstraZeneca plc trades at $157.98 (market cap $245.16B), while Boston Scientific Corporation trades at $52.92 (market cap $74.52B). The key difference: AstraZeneca plc is far larger — about 3.3× Boston Scientific Corporation's market cap, and AstraZeneca plc pays a 2.02% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| AZN | BSX | |
|---|---|---|
Market Cap | $245.16B | $74.52B |
Sector | Health | Health |
52-Week High | $209.48 | $108.14 |
52-Week Low | $147.06 | $42.63 |
Enterprise Value | $272.43B | $86.60B |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.24, down 0.95% on the day, amid bearish technical signals and merger speculation. The company shows strong fundamentals with revenue growth from $44.4B in 2022 to $58.7B in 2025 and net income margin improving to 17.4%. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing selling pressure and legal investigations creating near-term uncertainty.
AZN presents a mixed outlook with strong pharmaceutical fundamentals offset by technical weakness and merger-related volatility. The investment case hinges on continued earnings growth and strategic execution, while risks include integration challenges from potential M&A and ongoing legal scrutiny. Wall Street remains predominantly bullish despite recent price pressure.
Boston Scientific (BSX) trades at $51.69, up 0.98% today, with a bullish technical outlook supported by moving averages despite overbought RSI readings. The company shows strong fundamentals with Q2 2026 EPS of $0.86 beating estimates and revenue growth to $20.07B in 2025, alongside improving net income margins. Analyst sentiment is overwhelmingly positive with 86% buy ratings and a $67.21 consensus price target, though recent news highlights guidance cuts and competitive pressures in key segments like WATCHMAN.
The stock presents a compelling long-term opportunity given robust earnings growth and institutional confidence, but faces near-term risks from execution challenges and market volatility. Upside potential exists if the company stabilizes guidance and leverages new product catalysts, making it attractive for investors with a tolerance for sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
